Gossamer Bio
IPO
Transforming the lives of patients with pulmonary arterial hypertension.
- Employees
- 51–200
- Business Model
- B2B
- Website
- gossamerbio.com
- Total Funding
- $762.0M
- Last Round
- $212.0M Private EquityJul 2023
About
Gossamer Bio, founded in 2015 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company listed on Nasdaq (GOSS). The company is focused on the development and commercialization of seralutinib, an inhaled kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). Gossamer raised $317 million in its 2019 IPO and has a global collaboration with the Chiesi Group for seralutinib development, providing milestone payments and cost reimbursements.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account